Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C18H17N3O2 |
| Molecular Weight | 307.3465 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CNC(=O)C1=CC=C2C=C(C=CC2=C1)[C@]3(O)CCN4C=NC=C34
InChI
InChIKey=OZPFIJIOIVJZMN-GOSISDBHSA-N
InChI=1S/C18H17N3O2/c1-19-17(22)14-3-2-13-9-15(5-4-12(13)8-14)18(23)6-7-21-11-20-10-16(18)21/h2-5,8-11,23H,6-7H2,1H3,(H,19,22)/t18-/m1/s1
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Development and validation of an enantioselective LC-MS/MS method to quantify enantiomers of (±)-TAK-700 in rat plasma: lack of in vivo inversion of (+)-TAK-700 (Orteronel) to its antipode. | 2013-02 |
|
| Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer. | 2011-11-01 |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
752243-39-3
Created by
admin on Mon Mar 31 23:18:44 GMT 2025 , Edited by admin on Mon Mar 31 23:18:44 GMT 2025
|
PRIMARY | |||
|
DTXSID90226191
Created by
admin on Mon Mar 31 23:18:44 GMT 2025 , Edited by admin on Mon Mar 31 23:18:44 GMT 2025
|
PRIMARY | |||
|
267WB8R4TI
Created by
admin on Mon Mar 31 23:18:44 GMT 2025 , Edited by admin on Mon Mar 31 23:18:44 GMT 2025
|
PRIMARY | |||
|
10335364
Created by
admin on Mon Mar 31 23:18:44 GMT 2025 , Edited by admin on Mon Mar 31 23:18:44 GMT 2025
|
PRIMARY |
SUBSTANCE RECORD
